| 词条 | Patisiran |
| 释义 |
| drug_name = | INN = | type = | IUPAC_name = | image = Patisiran.png | width = 300 | alt = | caption = | pronounce = | tradename = Onpattro | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1420706-45-1 | class = | ATCvet = | ATC_prefix = N07 | ATC_suffix = XX12 | PubChem = | DrugBank = DB14582 | UNII = 50FKX8CB2Y | KEGG = D11116 | synonyms = ALN-18328 | C=412|H=520|N=148|O=290|P=40 | StdInChIKey = UBJHFPNBJDGZHL-UHFFFAOYSA-N }}Patisiran (trade name Onpattro) is a medication for the treatment of polyneuropathy in people with hereditary transthyretin-mediated amyloidosis. Hereditary transthyretin-mediated amyloidosis is a fatal rare disease that is estimated to affect 50,000 people worldwide.[1] It is the first small interfering RNA-based drug approved by the FDA and the first drug approved by the FDA to treat this condition.[1] It is a gene silencing drug that interferes with the production of an abnormal form of transthyretin. Patisiran was developed and is marketed by Alnylam. HistoryPatisiran was granted orphan drug status, fast track designation, priority review and breakthrough therapy designation due to its novel mechanism and the rarity of the condition it treats.[2][3] It was approved by the FDA in August 2018 and is expected to cost around $345,000 to $450,000 per year.[4] References1. ^1 {{cite news|url=https://www.wsj.com/articles/fda-approves-first-drug-based-on-gene-silencing-research-1533923359|title=New Kind of Drug, Silencing Genes, Gets FDA Approval|last1=Loftus|first1=Peter|date=10 August 2018|work=Wall Street Journal|accessdate=10 August 2018}} {{nervous-system-drug-stub}}2. ^{{cite press release |author= |title=FDA approves first-of-its kind targeted RNA-based therapy to treat a rare disease |url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616518.htm |location= |publisher=U.S. Food and Drug Administration |agency= |date=10 August 2018 |access-date=11 August 2018}} 3. ^{{cite web|url=https://www.medscape.com/viewarticle/900541|title=FDA OKs Patisiran (Onpattro) for Polyneuropathy in hAATR|last=Brooks|first=Megan|date=10 August 2018|website=Medscape|publisher=WebMD|archive-url=|archive-date=|dead-url=|accessdate=10 August 2018}} 4. ^{{cite web|url=https://www.bloomberg.com/news/articles/2018-08-10/alnylam-wins-first-u-s-drug-approval-in-rare-genetic-disease|title=Rare-Disease Treatment From Alnylam to Cost $450,000 a Year|last=Lipschultz|first=Bailey|last2=Cortez|first2=Michelle|date=10 August 2018|website=Bloomberg|archive-url=|archive-date=|dead-url=|accessdate=11 August 2018}} 3 : Drugs|Biopharmaceuticals|Orphan_drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。